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ABSTRACT
Purpose: Interferon is approved for adjuvant treatment of patients with stage IIb/III melanoma. The toxicity and
uncertainty regarding survival benefits of interferon have qualified its acceptance, despite significant durable
relapse prevention in a fraction of patients. Predictive biomarkers that would enable selection of patients for
therapy would have a large impact upon clinical practice. Specific CTLA-4 polymorphisms have previously shown
an association with response to CTLA-4 blockade in patients with metastatic melanoma and the development of
autoimmunity.
Experimental design: 286 melanoma patients and 288 healthy controls were genotyped for six CTLA-4
polymorphisms previously suggested to be important (AG 49, CT 318, CT 60, JO 27, JO30 and JO 31). Specific allele
frequencies were compared between the healthy and patient populations, as well as presence or absence of these
in relation to recurrence. Alleles related to autoimmune disease were also investigated.
Results: No significant differences were found between the distributions of CTLA-4 polymorphisms in the
melanoma population compared with healthy controls. Relapse free survival (RFS) and overall survival (OS) did not
differ significantly between patients with the alleles represented by these polymorphisms. No correlation between
autoimmunity and specific alleles was shown. The six polymorphisms evaluated where strongly associated (Fisher’s
exact p-values < 0.001 for all associations) and significant linkage disequilibrium among these was indicated.
Conclusion: No polymorphisms of CTLA-4 defined by the SNPs studied were correlated with improved RFS, OS, or
autoimmunity in this high-risk group of melanoma patients.
Introduction
Interferon alfa (IFNa) was the first cytokine to demon-
strate antitumor activity in patients with advanced mela-
noma and has been widely tested as adjuvant therapy in
patients at intermediate and high risk of melanoma
recurrence and associated mortality. Adjuvant treatment
of patients with stage IIB/III melanoma with high-dose
IFNa (HDI)was approved by the United States Food and
Drug Administration (FDA) in 1995, and subsequently
by regulatory authorities worldwide [1]. Despite the
ability of this regimen to reduce relapse and mortality
by up to 33% [2] the tolerability of this regimen has
been an issue, due to the frequent occurrence of flu-like
symptoms, including fatigue and anorexia, as well as
hepatic abnormalities and occasional depression.
Attempts to identify the subset of patients destined to
b e n e f i tf r o ma d j u v a n tt r e a t m e n tw i t hI F N a-2b have
failed to discover clinical or demographic features of the
patient population most likely benefit from HDI therapy
Correlative studies have been undertaken over the years,
demonstrating a variety of immunological responses sub-
sequent to therapy [3,4]. There is a critical need for
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related variables that predict clinical benefit from IFNa-
2b. The identification of predictive markers would permit
selection of patients likely to benefit and would enable
the 66% of patients unlikely to benefit to avoid the atten-
dant toxicity. The immunotherapies that benefit
advanced melanoma include IL-2, which has also been
shown to induce autoimmune reactions, thyroiditis, and
vitiligo. [5-14], A variety of autoimmune phenomena
have been reported to occur during adjuvant therapy
w i t hH D I .I nas u b s t u d yo fal a r g er a n d o m i z e dt r i a lo f
HDI in patients with stage IIB/III melanoma, 26% of 200
patients developed antithyroid antibodies or other auto-
immune manifestations [15]. The appearance of autoanti-
bodies or clinical manifestations of autoimmunity was
associated with significant improvements in relapse-free
(RFS) and overall survival (OS) (p < .001). This suggested
that the induction of autoimmunity could be a surrogate
marker for interferon efficacy. However, as autoimmunity
was observed only after a median of three months –and
in some instances, more than a year from the start of
IFNa-2b therapy, the development of autoimmunity per
se could not serve as a criterion for selecting patients to
initiate therapy.
The human CTLA-4 gene is located on chromosome
2q33, in a region that is associated with susceptibility for
autoimmune disease [16]. Multiple polymorphisms within
the CTLA-4 gene have been found to be associated with
susceptibility to autoimmune diseases (e.g., the GG allele
of the +49 AG polymorphism is associated with decreased
expression of CTLA-4 upon T-cell activation and thus a
higher proliferation of T-cells) [17-20]. Additionally, in a
phase I study of 19 patients receiving anti-CTLA-4 mono-
clonal antibody with multiple melanoma peptides and
Montanide ISA 51, three of four (75%) patients with the
CTLA-4 allele JO 30 (GG) developed autoimmune symp-
toms, and only two (50%) experienced disease relapse. Of
the remaining 15 patients expressing either the AA or AG
alleles, only five (33%) developed autoimmune symptoms
and 10 (67%) experienced disease relapse [21].
We therefore evaluated six CTLA-4 Single Nucleotide
Polymorphisms (SNPs) in a cohort of high-risk mela-
noma patients enrolled in a study of two regimens of
HDI, and compared the distribution of these SNPS to
those found in healthy controls (healthy unrelated indivi-
duals from the Donor Marrow Registry of the National
Tissue Typing Center, Athens, Greece). The correlation
of the CTLA-4 polymorphisms associated with the devel-
opment of autoimmune diseases and the HLA Cw*06
allele which predisposes to psoriasis was also studied as a
consequence of our observation that this allele was asso-
ciated with the disease outcome and induction of autoim-
munity in patients treated with adjuvant HDI [22].
Materials and Methods
Materials
We genotyped DNA isolated from the peripheral blood
of a total of 286 patients with melanoma and a panel of
288 randomly selected healthy unrelated Greek indivi-
duals that served as a control population, for 6 CTLA4-
S N P s ,n a m e l yC T6 0 ,A G4 9 ,C T3 1 8,J O2 7 ,J O3 0
and JO 31. CT 318 is located within the promoter
region of the CTLA-4 gene, A/G49 is located at exon 1,
while the rest of the SNPs tested are located at the 3’
untranslated region of CTLA-4.
Patients participating in this study were enrolled in
Trial 13A/98, a prospective, multicenter, randomized
phase III trial conducted at 13 institutions by the Helle-
nic Cooperative Oncology Group (HeCOG). This trial,
enrolled 364 patients with histologically documented
AJCC stage IIB, IIC, or III primary cutaneous melanoma
between 1998 and 2004. For patients with clinically unin-
volved lymph nodes, stage was defined pathologically
using sentinel lymph node (SLN) biopsy. Any patient
with a positive SLN was required to undergo completion
lymphadenectomy. All patients were assigned at random
to receive one of the two treatment regimens within
2 months of initial surgery or 1.5 months of therapeutic
lymph node dissection. The regimens used were a modi-
fication of the E1684 regimen [23]. Group A patients
received IFN-a2b (15 MIU/m
2/day IV 5 days per week
for 4 weeks) followed by observation. Group B patients
received the same induction dose for 4 weeks followed by
subcutaneous therapy (10 MIU/day TIW) for an addi-
tional 48 weeks. The primary endpoints for the core pro-
tocol were RFS and OS by treatment group.
The CTLA-4 polymorphism sub-study reported here
was conducted retrospectively in four institutions that had
participated in the core protocol. This substudy had sepa-
rate IRB approval, and all patients had provided written
informed consent for provision of biological material for
such future research studies at initiation of treatment.
Blood samples for evaluation of CTLA-4 were drawn prior
to treatment at the same time as samples for routine initial
visit blood tests. The first 10 mL of blood collected was
used for standard biochemistry and blood cell counts, and
the second 3 mL was used for CTLA-4 testing.
The clinical outcome of patients was prospectively fol-
lowed using standardized testing. Clinical staging con-
sisted of medical history, physical exams, blood cell
counts, blood biochemistry at 3-month intervals, and
chest x-ray and liver ultrasound at 6-month intervals.
Methods
DNA was isolated using the GenoPrep extraction sys-
tem (GenoVision, Oslo, Norway) and the SNP-PCR
was carried out with the following primers: CT 318
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biotinylated-GGTTTAGCTGTTACGTCGAAAAGA,
AG 49 forward TTTCAGCGGCACAAGGCTC, reverse
biotinylated-GAGTGCAGGGCCAGGTCC, CT 60 for-
ward GCAAGTCATTCTTGGAAGGTATC, reverse
biotinylated-TGCCAATTGATTTATAAAGGACTG,
JO 27 forward GAGCTGGTCAGCCGAGAT, reverse
biotinylated- TGACACCACCCCTCCATAAT, JO 30
forward CAAAGCAAAACGCTGCCAATAA, reverse
biotinylated- TCCAGTGGCAATAGGAGCTTTC, JO
31 forward TTGTCATGTTAGCCGTGCAGC, reverse
biotinylated- CCACCACCACACCCAGGTAA. 50 ng of
DNA were amplified in a 50 μL reaction containing 25
μL MasterMix (Illustra HotStart MasterMix, GE Health-
care, Buckinghamshire, UK) 1 μL (10 pmol) of each pri-
mer and denaturized water. PCR conditions were as
follows: first, a 5 minute incubation at 95°C was per-
formed, followed by 45 cycles of a 15 seconds denatura-
tion step at 95°C, 30 seconds annealing step at 56°C and
15 seconds extension step at 72°C. There was a final
extension step at 72°C for 5 minutes. We then geno-
typed the amplicons using Pyrosequencing technology
(Biotage, Uppsala, Sweden). The PCR strand which was
labeled by the biotinylated primer was captured on
Streptavidin Sepharose™ High Performance beads (GE
Healthcare, Uppsala, Sweden) and washed for 10 sec-
onds in 70% ethanol to remove PCR residuals. Single-
stranded DNAs were prepared after denaturation for 10
seconds with Denaturation Solution (Biotage, Uppsala,
Sweden) and then they were treated for 5 seconds with
appropriate Washing Buffer (Biotage, Uppsala, Sweden).
Hybridization of sequencing primers to respective tem-
plates was carried out according to the standard proto-
col described by the manufacturer (Biotage, Uppsala,
Sweden). All of the sequencing reactions were per-
formed on the PyroMark™ ID pyrosequencer, using the
PSQ 96 SNP Reagent Kit (Biotage AB) and analysis was
done with PyroMark™ ID 1.0 software. The sequencing
primers used were: 318C/T CACTTAGTTATCCA-
GATCCT, AG 49 GCTCAGCTGAACCTG, CT 60 TCA
CCACTATTTGGGATAT, JO 27 TACCAGAAGTT
GAAGTGTAG, JO 30 TCTGTCAGCAAAGCC, and JO
31 ACCTCTTGAGGTCAGGAGT http://hapmap.ncbi.
nlm.nih.gov/index.html.en.
Statistical Analysis
Allele frequencies were defined as follows: Each indivi-
dual was used as a unit and a particular allele was noted
as present if detected in an individual. Specific allele fre-
quencies were calculated both for the patient population
and the healthy control population. Fisher’s exact test
was used for comparing the frequency of specific alleles
(one observation per patient) between the healthy and
patient populations as well as the frequency of
recurrence between the population where the specific
allele was present versus the population it was absent.
In addition, recurrence and specific allele frequencies
were compared between patients with and without auto-
i m m u n er e s p o n s e sa sw e l la sH L A - C w * 0 6 S u r v i v a lw a s
evaluated from the date protocol treatment was started
to the date of last follow-up or date of death from any
cause. RFS was calculated from the initiation of treat-
ment to the date on which relapse was first documented
or on which death without documented relapse occurred.
The Kaplan-Meier method was used for the estimation of
RFS and OS curves. The reverse censoring method was
used for calculating descriptive statistics for the follow-
up time [24].
Cox regression analyses on RFS and OS were per-
formed, evaluating the association of outcome to the
presence of polymorphisms of CTLA-4 (AG 49, CT 60,
CT 318, JO 27, JO 30, JO 31), as well as of the most fre-
quent haplotypes. The combined effects of HLA-Cw*06,
AG 49 and the presence of autoimmunity on RFS and
OS were explored through a multivariate Cox model.
Maximum likelihood estimates of haplotype frequen-
cies given a multilocus sample of genetic marker geno-
types [3 different genotypeso ft h e6p o l y m o r p h i s m s ]
were generated using the expectation-maximization
(EM) algorithm under the assumption of Hardy-Wein-
berg equilibrium (HWE). Linkage disequilibrium was
explored for each pair of the 6 polymorphisms (PROC
HAPLOTYPE). SAS 9.1 (SAS Institute Inc., Cary, NC,
USA), was used for the statistical analysis.
Results
The frequency patterns of CTLA-4 alleles were first
evaluated in the healthy control and melanoma popula-
tions. There were no statistical differences in the inci-
dence of CTLA-4 polymorphisms between melanoma
patients and healthy controls (Table 1), except for JO
31, where the T/T allele was higher in controls (33.3%
vs 24.3%) while G/G and G/T was lower (p = 0.047).
Patient demographics and baseline characteristics have
been described elsewhere [15,23]. With a median follow
up of 70.7 months [only among patients alive (censored
values), range 7.1-138.7 months], there were 158 recur-
rences (median RFS 55 months, range 1 to 115 months)
and 105 deaths (median OS not reached yet, range 2 to
86 months).
RFS and OS did not differ significantly between
patients with the alleles represented by these poly-
morphisms. Τhe corresponding p-values for RFS and OS
are presented in Table 2 and Figures 1,2,3,4,5,6. In addi-
tion, RFS and OS did not differ significantly in the
cohort of patients with AG 49 GG when compared with
patients with AG49 AA or AG (p = 0.5 and p = 0.51
respectively). No differences were again demonstrated
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with the cohort of patients either heterozygous or
homozygous to the protective allele (p = 0.38 and p =
0.58, and p = 0.92 and p = 0.38 respectively).
High association between the different polymorphisms
was found (Fisher’s exact p-value < 0.001 for all associa-
tions). Genotypes corresponding to the six CTLA-4
polymorphisms did not significantly deviate from
the Hardy-Weinberg equilibrium. The test indicates
significant linkage disequilibrium among the six
polymorphisms
We analyzed the segregation pattern of CT 318, AG
49, CT 60, JO 27, JO 30, JO 31 SNPs on 572 chromo-
somes and identified 5 major haplotypes (table 3). No
statistically significant differences for RFS or OS were
found for the presence of each of the 3 most common
haplotypes.
The association of Cw*06 with the CTLA-4 alleles was
investigated and a statistically significant association was
found with AG 49 (p = 0.023). In patients with positive
Cw*06, 61.8% were AG 49 AA, 29.1% were AG 49 AG
and 9.1% were AG 49 GG. The median relapse-free sur-
vival for Cw*06 positive patients with genotype AG 49
AG was 76.4 months and has not been reached yet for
genotypes AA and GG. In Cw*06 negative patients the
median relapse-free survival for genotypes AG49 AA,
AG and GG was 56.7, 36.2 and 24.6 respectively. Med-
ian overall survival has not been reached yet in Cw*06
positive patients in all three genotypes (AG 49 AA, AG,
GG) and in the Cw*06 negative cohort it was 86. 1, 66.7
and 61.2 months, respectively. However, no statistically
significant differences were found for HLA Cw*06 posi-
tive patients in terms of RFS or OS, among AG 49
groups (p = 0.62 and p = 0.46 respectively). Likewise, no
statistically significant differences were found for HLA
Cw*06 negative patients in terms of RFS and OS among
A/G 49 groups (p = 0.42 and p = 0.39 respectively). RFS
and OS did not differ significantly in the cohort of
patients with AG 49 GG vs AG/AA positive for HLA
Cw*06 (p = 0.37 and p = 0.23 respectively) or negative
for HLA Cw*06 (p = 0.22 and p = 0.22 respectively). In
the cohort of patients included in the prospective auto-
immune study, CTLA-4 polymorphisms were investi-
gated in 157 out of 200 patients (48 autoimmunity
group and 109 without evidence of autoimmunity). No
statistically significant association was found among any
of the six polymorphisms investigated. In the multivari-
ate Cox model for RFS and OS, HLA Cw*06 and auto-
immunity were statistically significantly correlated with
RFS (p = 0.043 and p < 0.001 respectively), while only
autoimmunity was found to be statistically significant
for OS (p = 0.001).
Discussion
This study analyzed the potential influences of the
CTLA-4 genotype upon the outcome of IFN adjuvant
therapy, on the basis of prior suggestions of the role of
certain polymorphisms of the CTLA-4 gene and other
immunotherapies for patients with melanoma. To
answer these questions it was first necessary to define a
baseline population for comparison. No database was
available that describes the prevalence of CTLA-4 alleles
among the Greek population, nor of melanoma patients
from Greece. Several groups have reported analyses of
the CTLA-4 genotypes of Caucasian and Japanese popu-
lations, yielding differing results [19,25,26]. Our results
in the healthy Greek control population are similar to
the allele frequencies identified in a population of 536
healthy Spanish haemopoietic stem cell donors that
evaluated the association of CTLA-4 polymorphisms of
patients and the post transplant outcome [27]. No sig-
nificant differences were seen among the CTLA-4 pro-
files of the Greek healthy control and melanoma
populations studied here.
Table 1 Frequencies of CTLA-4 polymorphisms in
melanoma patients and healthy controls
Controls Melanomas
Number (N = 288) % Number (N = 286) % P
AG 49
A/A 152 52.8 132 46.2 0.27
A/G 111 38.5 128 44.8
G/G 25 8.7 26 9.1
CT 318
C/C 230 79.9 229 80.1 0.94
C/T 57 19.8 55 19.2
T/T 1 0.4 2 0.7
CT 60
A/A 90 31.3 65 22.7 0.071
A/G 135 46.9 151 52.8
G/G 63 21.9 70 24.5
JO 27
C/C 90 31.3 73 25.5 0.32
C/T 143 49.7 153 53.5
T/T 55 19.1 60 21.0
JO 30
A/A 95 33.0 72 25.2 0.12
A/G 138 47.9 151 52.8
G/G 55 19.1 63 22.0
JO 31
T/T 96 33.3 71 24.8 0.047
G/T 144 50.0 151 52.8
G/G 48 16.8 64 22.4
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been linked with an increased risk for multiple autoim-
mune diseases [17-19,25,26]. Intriguingly, a CTLA-4
polymorphism conferring low-level expression was
found to be associated with higher frequencies of auto-
immune toxicity among 19 melanoma patients treated
concurrently with MDX-010 (ipilimumab) anti-CTLA-4
monoclonal antibody and a melanoma peptide vaccine
[21]. An important result of this trial was the suggestion
that the incidence of tumor relapse might be reduced
among patients manifesting autoimmune toxicity. An
earlier trial of concurrentM D X - 0 1 0a n dm e l a n o m a
peptide vaccination also raised this possibility [28,29].
These provocative findings stimulated detailed investiga-
tion of the polymorphisms of CTLA-4 in larger numbers
of patients treated in a subsequent study of 152 stage IV
melanoma patients at the NIH. These investigators eval-
uated 7 common nucleotide polymorphisms and showed
three SNPs to be associated with response to anti-
CTLA4 antibody therapy: -1660AG, -657TC and AG 49.
A haplotype analysis including the same 7 SNPs sug-
gested that the common haplotype TACCGGG was
associated with non-response (p = 0.02) whereas the
haplotype TGCCAGG was associated with response to
Table 2 Univariate Cox Regression Models of Relapse-free Survival and Overall Survival
No of events/No of
patients
Median Relapse- free Survival
(months)
P
value
No of events/No of
patients
Median Overall Survival
(months)
P
value
AG 49
A/
A
71/132 59.56 0.55 47/132 NR* 0.55
A/
G
70/128 46.42 47/128 84.20
G/
G
17/26 35.35 11/26 63.38
CT 318
C/
C
122/229 54.67 0.52 82/229 NR 0.36
C/T 34/55 47.67 21/55 NR
T/T 2/2 37.35 2/2 51.02
CT 60
A/
A
34/65 58.87 0.68 23/65 NR 0.64
A/
G
85/151 47.67 54/151 84.20
G/
G
39/70 53.22 28/70 76.68
JO 27
C/
C
37/73 58.87 0.60 26/73 NR 0.76
T/C 84/153 54.67 54/153 84.20
T/T 37/60 37.29 25/60 76.68
JO 30
A/
A
37/72 56.71 0.65 27/72 NR 0.74
G/
A
83/151 54.80 52/151 NR
G/
G
38/63 37.29 26/63 76.68
JO 31
T/T 35/71 72.08 0.37 23/71 NR 0.50
G/
T
85/151 47.67 56/151 80.69
G/
G
38/64 39.43 26/64 76.68
* NR: Not Reached
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observed among the occurrences of severe autoimmune
reactions (grade III/IV) in patients with either single
SNP or haplotype analyses [30].
The present cohort of patients with high risk melanoma
has shown no correlation of any of the polymorphisms of
CTLA-4 defined by the SNPs studied and improved RFS
or OS, with adjuvant HDI treatment. Similarly, among 90
patients with stage IIB, IIC and III melanoma treated with
HDI, AG 49 and CT 318 genotypes did not correlate with
improved RFS and OS (Henry Koon, personal communi-
cation). There was a trend towards improved survival in
the group with AG 49 AA (p = 0.06). The A allele of AG
49 was significantly associated with response (p = 0.009)
among the 152 patients with stage IV melanoma treated
with ipilimumab [30]. In the present study population,
patients with the AG 49 AA allele had a better RFS and
OS, but this did not reach statistical significance. This was
also the case with the CT 60AA allele. The A allele at CT
60 has been identified as being responsible for a greater
production of the soluble form of CTLA4 (s-CTLA4)
[19,27], reflecting T-cell activation [31,32].
The GG allele was not associated with the development
of autoimmunity in the cohort of patients retrospectively
s t u d i e dh e r e .I nt h eN I HS t u d y[ 3 0 ]a l l e l ef r e q u e n c i e s
were also compared between groups of patients who
developed autoimmune reaction of grade III/IV and
those who did not–but no significant difference was
observed. These findings may support the hypothesis that
“induced autoimmunity” by IFN, IL-2, CTLA-4 blockade
that is often a reversible process is a different process
from spontaneous autoimmune disease. On the other
hand, independent of genetic variation in CTLA-4, there
was a strong positive association among response to the
treatment and grade III/IV toxicity (p < 0.002) [30], as
previously reported [28,29], and shown in our previously
published work [15]. Failure to demonstrate the
Figure 1 RFS plot by A/G 49 status.
Figure 2 OS plot by A/G 49 status.
Figure 3 RFS plot by C/T 318 status.
Figure 4 OS plot by C/T 318 status.
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4 polymorphisms might indicate that the IFNa2b-related
induction of autoimmunity in melanoma patients differs
from spontaneously occurring autoimmune disorders
with respect to the genetics of CTLA-4 and presumably,
also in other aspects of this multi-factorial process. Thus,
different routes to the development of autoimmunity
may be associated with different sets of genes. Neverthe-
less, it is most interesting that a statistically significant
association was found between HLA-Cw*06 and AG 49
allele distribution (p = 0.023). Although no statistical
association was found between AG 49 alleles and RFS or
OS, for HLA- Cw*06 positive patients, the ones with the
GG genotype seemed to fair better regarding RFS and
OS. Only one out of five patients had relapsed and all
were alive. These results are limited by the small sample
size and should be further explored in other trials of
IFN-a2b of the US and European cooperative groups.
Our investigation into the association of CLTA-4 poly-
morphisms and the results of interferon therapy in a
population where the occurrence of autoimmunity has
been rigorously prospectively characterized, assumes that
the predominant effect of CTLA-4 polymorphisms is upon
T-cell responsiveness. The CT 60AA allele is associated
with increased circulating levels of soluble CTLA-4, which
adds another layer of complexity to these studies. Soluble
CTLA-4 binds to CD80/86 and in vitro suppresses prolif-
eration of committed autoreactive T cell clones in a dose-
dependent manner [33]. However its function in vivo is
unclear as s-CTLA-4 expression has been reported to cor-
relate with the occurrence of autoimmunity. This dichot-
omy may reflect the fact that the effect of s-CTLA-4 is
mediated by cells other that T-cells or that the expression
of s-CTLA-4 during T-cell activation results in increased
T-cell responsiveness, through inhibition of CTLA-4 liga-
tion with CD80/86. Measurement of the pretreatment pro-
tein levels of s-CTLA-4 may give us more insight into the
association between CTLA-4 polymorphisms and the clin-
ical outcome of IFN therapy among patients receiving
adjuvant interferon therapy or antibody mediated CTLA-4
blockade. These studies are now being planned.
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